ישראל -
עברית -
Ministry of Health
שמן מור אורגני ארומטי- חיוני לעור יבש עד יבש מאוד
אלקליל בעמ - הזנה לפנים
ישראל -
עברית -
Ministry of Health
פיור אויל שמן הדס
תמר שיווק מוצרי בריאות טבעיים בעמ - מסג', אמבט וטיפוח העור
ישראל -
עברית -
Ministry of Health
דביגטרן אס.קיי 110 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 110 mg - dabigatran etexilate
ישראל -
עברית -
Ministry of Health
דביגטרן אס.קיי 75 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 75 mg - dabigatran etexilate
ישראל -
עברית -
Ministry of Health
דביגטרן אס.קיי 150 מג
k.s.kim international ltd - dabigatran etexilate - קפסולות - dabigatran etexilate 150 mg - dabigatran etexilate
ישראל -
עברית -
Ministry of Health
דולוקס טבע 30 מג
abic marketing ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 30 mg - duloxetine
ישראל -
עברית -
Ministry of Health
דולוקס טבע 60 מג
abic marketing ltd, israel - duloxetine as hydrochloride - duloxetine as hydrochloride 60 mg - duloxetine
ישראל -
עברית -
Ministry of Health
קלופידוגרל טבע
teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or